What is Genesis Therapeutics?
AI-native small-molecule drug discovery company using GEMS to design medicines for hard targets.
- Category
- AI drug discovery
- Headquarters
- Burlingame, CA
- Founded
- 2019
- Employees
- 100-250 estimated
- Total funding
- $304M+ disclosed/compiled
- Status
- Private; Series B+
What is Genesis Therapeutics?
Genesis Therapeutics builds AI systems and drug programs for small-molecule therapeutics, with GEMS as its core molecular design platform.
Genesis Therapeutics is an AI and biotech company applying molecular AI, physics-based simulation, wet-lab feedback, and medicinal chemistry to small-molecule drug discovery. Its GEMS platform supports internal pipeline programs and strategic collaborations with Gilead and Incyte. The company is in a16z's public investment list, which confirms Andreessen Horowitz portfolio provenance for this profile.
Genesis competes in the AI-enabled drug-discovery market where pharma buyers care about validated biology, differentiated chemistry, and partner economics rather than generic model demos. Revenue is not public; public commercial signals are collaboration payments such as a $35 million Gilead upfront and a $30 million Incyte upfront. As of June 2026, the most useful seller read is that budgets cluster around compute, AI infrastructure, lab operations, translational science, security, and pharma-partner delivery.
The company rebranded around Genesis Molecular AI while preserving the Genesis Therapeutics legal and portfolio identity. The company remains private and venture-backed, so private revenue, exact customer concentration, and current cap-table details should be treated as unavailable unless management publishes them.
What does Genesis Therapeutics offer?
Genesis offers an internal drug-discovery pipeline and partner-facing AI discovery collaborations.
- GEMS molecular AI platform· AI platform
- Small-molecule discovery· Pipeline
- AI + wet-lab flywheel· Drug discovery
- Gilead collaboration· Partnership
- Incyte collaboration· Partnership
- Pearl structure prediction· Foundation model
How does Genesis Therapeutics make money?
Genesis makes money through pharma collaborations, milestone economics, and long-term pipeline ownership rather than published SaaS pricing.
Genesis is not a self-serve software vendor. It monetizes by combining proprietary AI models, computational chemistry, wet-lab validation, and drug-program execution in internal and partnered programs.
No public per-seat or platform price list exists. Public economics include a Gilead collaboration with a $35 million upfront payment for three initial targets and an Incyte collaboration with a $30 million upfront payment and potential milestone economics.
Growth is driven by higher-confidence hit discovery, partner expansion, clinical advancement of internal programs, and efficient GPU-enabled model training. For vendors, the practical budget owners are usually AI platform leaders, computational chemistry, discovery biology, business development, procurement, and security.
Who leads Genesis Therapeutics?
Genesis is led by co-founder and CEO Evan Feinberg with CTO Sergey Edunov, COO Will McCarthy, and CSO Shifeng Pan.
- Evan Feinberg, Ph.D.CEO and co-founderFounded 2019Stanford-trained computational biophysicist behind Genesis and GEMS.
- Sergey EdunovChief Technology OfficerExecutive teamFormer large-scale AI infrastructure leader; owns technical platform direction.
- Will McCarthyChief Operating OfficerExecutive teamLeads operating execution as Genesis scales partnerships and pipeline work.
- Shifeng Pan, Ph.D.Chief Scientific OfficerJoined leadership team in 2024Owns scientific strategy and drug discovery execution.
How do you contact Genesis Therapeutics's leadership?
Genesis does not publish verified personal executive emails in reviewed sources; use its contact page for leadership routing.
Personal executive email format not verified; use the company contact page or public role-based aliasesHow much funding has Genesis Therapeutics raised?
Genesis Therapeutics has $304m+ disclosed/compiled and valuation not publicly disclosed.
Genesis Therapeutics's major disclosed financings are a 2020 $52 million Series A, a 2023 $200 million Series B co-led by a16z Bio + Health and a U.S. life-sciences investor, and additional compiled financing that brings public database totals above $300 million.
Genesis has not announced a priced valuation publicly. The Series B was earmarked for moving AI-enabled drug candidates toward the clinic, expanding GEMS, and growing the discovery pipeline.
Seller signal: fresh strategic collaborations and a large Series B indicate real budgets for compute, lab automation, model evaluation, and secure partner workflows, but biotech procurement will still be scientific-validation heavy.
How did Genesis Therapeutics get here?
Genesis moved from Stanford-origin research to a funded AI biotech with major pharma collaborations.
- 2019FoundedGenesis begins around AI and simulation research for small-molecule discovery.
- 2020Series ARaises $52M to build its drug-discovery platform.
- 2023Series BRaises $200M to expand platform and pipeline.
- 2024Gilead partnershipAnnounces multi-target collaboration with $35M upfront.
- 2025Incyte partnershipAnnounces AI small-molecule collaboration with $30M upfront.
- 2026Genesis Molecular AI positioningCompany emphasizes GEMS, Pearl, and AI + wet-lab discovery flywheel.
Who are Genesis Therapeutics's competitors?
Genesis competes with AI-native drug discovery companies and computational biology platforms.
- insitroBroader ML-native drug discovery platform with clinical and data assets.
- RecursionPublic industrialized biology and AI drug discovery company.
- SchrodingerPhysics-based molecular modeling software and drug discovery platform.
- ExscientiaAI-designed drug discovery company with pharma partnerships.
- Generate:BiomedicinesGenerative biology platform more focused on protein therapeutics.
Genesis Therapeutics — frequently asked questions
